Programs scale access to fertility preservation using Future Fertility’s oocyte assessment tool, Violet
This News Digest Is Paid Sponsored Content From
Future Fertility
The number of women electing to freeze their eggs in the US increased to 12,438 in 2020, up from 7,193 just four years prior in 2016, The Society for Assisted Reproductive Technology reported.
However, a limiting factor to fertility clinics’ egg-freezing programs has remained: patient confidence. Practitioners could not tell patients the quality of their eggs, making egg freezing programs an expensive and stressful gamble.
Some fertility clinics have been able to dramatically improve their egg freezing programs leveraging an AI-based oocyte assessment tool, Violet. This technology measures egg quality to gain an objective view of the probability of successful fertilization and blastocyst development to help clinics guide egg freezing cycles, empowering patients with personalized insights and improving confidence in clinic decision-making.
Growing clinics’ egg freezing programs through a stronger patient experience
The AI tool informs patients about their fertility health, helping to guide patients’ next steps and aiding practitioners in attracting patients to their egg freezing programs.
Professor Alison Campbell, Chief Scientific Officer at Care Fertility Group, first heard of Violet several years ago following a presentation by Future Fertility’s co-founder Dr. Dan Nayot, a reproductive endocrinologist. “I had to investigate!”, she shared.
“I was very skeptical about the power of AI to predict quality or viability potential from a photograph of oocytes in the IVF laboratory,” Professor Campbell added. With no standardized visual scoring system in place, evaluating oocyte quality had previously not been possible by embryologists.
Professor Campbell’s clinic network, Care, went on to become the first in the UK to adopt Violet and is now using the tool in all egg freezing cycles. “Having data like this from Violet helps clinic staff have more meaningful conversations with patients to support their decision-making and fertility planning,” she continued.
“The first question all patients opting for the oocyte freezing programs have, is how many oocytes they need to freeze to have a viable embryo,” said Dr. Ernesto Escudero, Gynecology Fertility Specialist at Inmater, a fertility clinic in Peru that has been using Violet for over a year now.
“Violet is a very helpful tool to show patients the real number of oocytes they need to store for, not just their age, but also for the viability of each oocyte,” he added.
These insights are guiding counselling conversations and helping patients connect the clinician’s treatment recommendations with their own personalized data – for example, when egg quality is lower than expected for their age and additional retrievals are recommended to give them the best chance of reaching their family planning goals.
Violet is also filling a gap in ensuring patients have appropriate expectations for the usage of the frozen eggs in the future – information that, until now, has been shared only in terms of general estimates, based on population health statistics that consider only the patient’s age and number of mature eggs retrieved.
Delivering this level of information and building a relationship of trust means these patients are more likely to return for future treatments, enabling clinics to grow their programs. This also helps create a positive reputation in the patient community, helping to attract new clients through differentiated service levels.
Dr. Sergio Papier, Medical Director and CEO of CEGYR in Argentina, attests to this approach – his clinic has adopted Violet as part of every freezing cycle as the clinic expands its precision medicine program. “It is a tool that we have quickly incorporated for all patients,” he says.
AI tools scale access to fertility preservation through standardization and repeatability
“AI has the potential to improve reliability, accuracy, efficiency, and reproducibility in the IVF lab and wider clinic,” Professor Campbell relayed. Using advanced deep learning technology to evaluate oocyte images, Violet answers the need for more certainty regarding oocyte quality.
“My concern has always been to have an objective biomarker that can evaluate oocyte quality, the most important variable in the results of ART,” said Dr. Papier. It was this interest that led Dr. Papier to discover Violet. The AI tool not only informs treatment planning but also provides clinics with new research projects, exploring the impact of clinical and lab variables on oocyte quality.
“It’s very important in a lab to have tools that will help achieve better pregnancy rates and reduce time to pregnancy – AI is the future for that,” comments Dr. Escudero.
Future Fertility’s technology has also proven to integrate seamlessly with existing lab set-ups and workflows. “It doesn’t need to alter what the clinical embryologists do with the eggs, in terms of cryopreservation, and it can help the team counsel patients, set their expectations, and aid their decision-making,” said Professor Campbell.
“Future Fertility makes AI accessible to IVF laboratories,” she highlighted, detailing how the company stands out as the go-to AI egg-freezing tool.
“They have a strong expert team and work closely with clinics to educate staff and implement their technology,” added Professor Campbell. Care Fertility has seen its egg freezing program grow since implementing the tech.
“Without a doubt, Violet is a very useful tool for evaluating oocyte quality and gives doctors, biologists and patients a more objective perspective of potential future results,” shared Dr. Papier.
This News Digest Story is paid featured sponsor content, where the Advertiser has editorial control. They do not reflect the views of Inside Reproductive Health.
Transform Your Clinic's Capabilities: Elevate Egg Freezing Success with VIOLET™ AI Insights
Advance your clinic's capabilities with VIOLET™, the forefront of AI technology in oocyte quality assessment. This revolutionary tool not only elevates your egg freezing services but also profoundly enriches the patient experience.
🌟 Enhanced Patient Experience: VIOLET™ provides clear, detailed oocyte quality reports, deepening patients' understanding and satisfaction. This transparency fosters a stronger bond of trust, making patients feel more involved and informed in their fertility journey.
🎯 Precision and Personalization: The AI-driven analysis by VIOLET™ leverages the industry’s largest and most diverse oocyte dataset to deliver precise predictions tailored to each patient. This empowers clinicians with vital insights to guide decision-making with patients.
📈 Clinic Growth through Trust: Offering such advanced, personalized assessments positions your clinic as a leader in fertility solutions, attracting patients who value more precise information and a differentiated experience.
🧠 Informed Clinical Decisions: VIOLET™ not only informs patients but also supports clinicians with robust data for enhanced treatment planning and counseling, leading to more confident and tailored patient care.
Grow your clinic's egg freezing program with VIOLET™
By completing the form below, you can access a complimentary sample of the VIOLET™ report, plus 3 key example patient scenarios where VIOLET™ can be used to bring your patient experience and treatment planning to the next level. Delve into the world of AI-enhanced fertility assessment and see how it can modernize your egg freezing programs for a growing area of need.
This News Digest Is Paid Sponsored Content From
Future Fertility
All external links active as of 1/18/24.
External links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Fertility Bridge or Inside Reproductive Health of any of the products, services or opinions of the corporation or organization or individual. Neither Fertility Bridge nor Inside Reproductive Health bears responsibility for the accuracy, legality or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.